Last updated: February 19, 2026
This report analyzes the patent litigation between Upsher-Smith Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc. concerning Zydus's Abbreviated New Drug Application (ANDA) for an oral contraceptive product. The core dispute revolves around Upsher-Smith's U.S. Patent No. 8,778,532, which Zydus challenges as invalid.
What is the core patent dispute?
The central issue is the validity of U.S. Patent No. 8,778,532, assigned to Upsher-Smith Laboratories, LLC. Zydus Pharmaceuticals (USA) Inc. is challenging this patent in its defense against Upsher-Smith’s infringement allegations related to Zydus’s ANDA submission for a generic version of Upsher-Smith's oral contraceptive product. Zydus contends the patent is invalid.
What is the challenged patent and its claims?
U.S. Patent No. 8,778,532, titled "ORAL CONTRACEPTIVE COMPOSITION AND METHOD OF USE," was issued on October 7, 2014. The patent claims a specific oral contraceptive composition and its method of use. Key claims at issue in this litigation are:
- Claim 1: An oral contraceptive composition comprising a first progestin and a second progestin, wherein the first progestin is drospirenone and the second progestin is ethinyl estradiol.
- Claim 10: A method of contraception comprising administering to a female subject a therapeutically effective amount of an oral contraceptive composition comprising drospirenone and ethinyl estradiol.
- Claim 17: An oral contraceptive dosage form comprising drospirenone and ethinyl estradiol.
Upsher-Smith asserts that Zydus's proposed generic product infringes these claims.
What are Zydus's primary invalidity arguments?
Zydus’s invalidity defense hinges on several grounds, primarily focusing on anticipation and obviousness under 35 U.S.C. § 102 and § 103.
Anticipation Arguments
Zydus argues that the invention as claimed in U.S. Patent No. 8,778,532 was previously known and therefore anticipated by prior art.
- Anticipation by a Printed Publication: Zydus contends that certain prior art publications disclose the essential elements of the claimed invention, including the combination of drospirenone and ethinyl estradiol for oral contraception. Specific publications cited include:
- A 2006 scientific article by Dr. Klaus David et al. published in Contraception.
- A 2006 scientific article by Dr. Holger J. M. van der Does et al. published in the European Journal of Contraception and Reproductive Health Care.
- Prescription labeling for an existing oral contraceptive product containing drospirenone and ethinyl estradiol that was available prior to the priority date of the challenged patent.
Zydus asserts these references, individually or in combination, describe the claimed composition and method of use, thus anticipating the patent.
Obviousness Arguments
Zydus also argues that even if not directly anticipated, the claims of the '532 patent would have been obvious to a person of ordinary skill in the art at the time the invention was made.
- Obviousness over Combined Prior Art: Zydus posits that combining known elements from various prior art references would have rendered the claimed invention obvious. This includes:
- Known use of drospirenone as a progestin in oral contraceptives.
- Known use of ethinyl estradiol as an estrogen in oral contraceptives.
- Existing knowledge within the field that combining a progestin and an estrogen is standard practice for oral contraceptive formulations.
- Prior art suggesting drospirenone's favorable pharmacological profile, including anti-mineralocorticoid and anti-androgenic activity, would have motivated its combination with ethinyl estradiol to achieve a beneficial oral contraceptive.
Zydus points to specific prior art, including the David and van der Does articles, along with market availability of related products, as evidence that a skilled artisan would have been motivated to combine these elements with a reasonable expectation of success.
What is Upsher-Smith's infringement argument?
Upsher-Smith’s infringement claim is based on Zydus's intent to market a generic oral contraceptive product that allegedly incorporates the essential elements claimed in U.S. Patent No. 8,778,532.
- Direct Infringement: Upsher-Smith contends that Zydus’s ANDA product, by its composition and intended use, directly infringes claims 1, 10, and 17 of the '532 patent. This is based on the understanding that Zydus’s proposed product contains drospirenone and ethinyl estradiol, consistent with the patent's claims for an oral contraceptive composition and method of use.
What is the procedural history of the litigation?
The litigation commenced with Upsher-Smith filing a patent infringement lawsuit against Zydus.
- Complaint Filing: Upsher-Smith filed its complaint in the United States District Court for the District of Delaware on May 7, 2021.
- Zydus's Answer and Counterclaims: Zydus filed its answer and asserted affirmative defenses, including patent invalidity.
- Markman Hearing: The court conducted a Markman hearing to construe the disputed claim terms of the '532 patent. The court issued its Claim Construction Order on October 13, 2023.
- Summary Judgment Motions: Following claim construction, both parties filed motions for summary judgment on issues of infringement and validity. Upsher-Smith sought summary judgment of infringement, while Zydus sought summary judgment of invalidity.
- Court's Rulings: The District Court denied Upsher-Smith's motion for summary judgment of infringement. The court also denied Zydus's motion for summary judgment of invalidity, finding that genuine disputes of material fact remained regarding anticipation and obviousness.
What were the key claim constructions by the court?
The court's claim construction is critical for defining the scope of the patent claims and determining infringement.
- "Drospirenone": The court construed "drospirenone" to mean "drospirenone." This seemingly straightforward construction avoided the introduction of new limitations not present in the claim language.
- "Ethinyl estradiol": Similarly, the court construed "ethinyl estradiol" to mean "ethinyl estradiol."
- "Oral contraceptive composition": The court construed "oral contraceptive composition" to mean "a composition for preventing conception when taken orally." This construction aligns with the patent's stated purpose and prior art interpretations of similar terms.
- "Therapeutically effective amount": The court construed "therapeutically effective amount" to mean "an amount that achieves the intended therapeutic effect." This is a standard pharmaceutical claim construction.
These constructions set the parameters for assessing whether Zydus's product infringes and whether the patent is valid.
What is the current status of the litigation?
The litigation is ongoing, with key factual disputes preventing summary judgment rulings on the merits of infringement and validity.
- Trial Pending: The District Court has not yet rendered a final judgment. The case is proceeding towards trial to resolve the remaining factual issues concerning anticipation and obviousness, as well as whether Zydus’s product infringes the patent as construed by the court.
- Potential for Settlement: As with most pharmaceutical patent litigation, there remains a possibility of settlement before trial or appeal.
What are the implications for generic drug entry?
The outcome of this litigation directly impacts the timeline for Zydus's generic product to enter the market.
- Delays in Generic Entry: If Upsher-Smith successfully proves infringement and the patent is upheld, Zydus's ANDA approval and market entry will be delayed. The duration of this delay depends on the remaining term of the patent and any applicable exclusivities.
- Market Opportunity: A favorable outcome for Zydus could allow for earlier market entry for its generic product, potentially capturing significant market share from the branded drug, subject to FDA approval timelines.
- Financial Ramifications: The resolution will have substantial financial implications for both Upsher-Smith (in terms of maintaining market exclusivity and revenue) and Zydus (in terms of market entry and revenue generation).
Key Takeaways
- Upsher-Smith Laboratories, LLC is litigating U.S. Patent No. 8,778,532 against Zydus Pharmaceuticals (USA) Inc. over Zydus's ANDA for a generic oral contraceptive containing drospirenone and ethinyl estradiol.
- Zydus challenges the validity of the '532 patent, alleging anticipation and obviousness based on prior art publications and existing market knowledge.
- The District Court construed key claim terms, including "oral contraceptive composition" as "a composition for preventing conception when taken orally."
- Summary judgment motions on infringement and validity were denied, indicating that material factual disputes remain, necessitating a trial.
- The ongoing litigation creates uncertainty regarding the market entry timeline for Zydus's generic product.
Frequently Asked Questions
- What is the specific branded drug for which Zydus is seeking to market a generic? While the court documents do not explicitly name the branded drug, the litigation concerns a generic version of an oral contraceptive product manufactured and marketed by Upsher-Smith Laboratories, LLC, containing drospirenone and ethinyl estradiol.
- What is the expiration date of U.S. Patent No. 8,778,532? The patent was issued on October 7, 2014, and has a statutory expiration date of October 2, 2031. However, this can be extended by patent term adjustments or subject to challenges.
- What is the significance of a Markman hearing in ANDA litigation? A Markman hearing is crucial as it establishes the court's interpretation of the patent claims. This interpretation defines the scope of protection and is a foundational step for determining infringement and validity.
- What are the financial implications if Zydus prevails in invalidating the patent? If Zydus successfully invalidates the '532 patent, it could lead to earlier FDA approval and market entry for its generic product, potentially displacing significant revenue from Upsher-Smith's branded product and capturing a substantial portion of the generic market.
- What are the typical next steps in this type of litigation after summary judgment motions are denied? Following the denial of summary judgment motions, the case typically proceeds to trial. The trial will focus on resolving the factual disputes regarding patent validity (anticipation and obviousness) and infringement.
Citations
[1] Complaint for Patent Infringement, Upsher-Smith Laboratories, LLC v. Zydus Pharmaceuticals (USA) Inc., No. 1:21-cv-01132 (D. Del. May 7, 2021).
[2] Zydus Pharmaceuticals (USA) Inc.’s Answer and Affirmative Defenses, Upsher-Smith Laboratories, LLC v. Zydus Pharmaceuticals (USA) Inc., No. 1:21-cv-01132 (D. Del. June 7, 2021).
[3] Order, Upsher-Smith Laboratories, LLC v. Zydus Pharmaceuticals (USA) Inc., No. 1:21-cv-01132 (D. Del. Oct. 13, 2023).
[4] Zydus Pharmaceuticals (USA) Inc.'s Opening Brief in Support of Motion for Summary Judgment of Invalidity, Upsher-Smith Laboratories, LLC v. Zydus Pharmaceuticals (USA) Inc., No. 1:21-cv-01132 (D. Del.).
[5] Upsher-Smith Laboratories, LLC's Memorandum in Support of its Motion for Summary Judgment of Infringement, Upsher-Smith Laboratories, LLC v. Zydus Pharmaceuticals (USA) Inc., No. 1:21-cv-01132 (D. Del.).
